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Peste des petits ruminants virus (PPRV) is a morbillivirus that can cause severe disease in sheep and goats,
characterised by pyrexia, pneumo-enteritis, and gastritis. The socio-economic burden of the disease is increasing in
underdeveloped countries, with poor livestock keepers being affected the most. Current vaccines consist of
cell-culture attenuated strains of PPRV, which induce a similar antibody profile to that induced by natural infection.
Generation of a vaccine that enables differentiation of infected from vaccinated animals (DIVA) would benefit PPR
control and eradication programmes, particularly in the later stages of an eradication campaign and for countries
where the disease is not endemic. In order to create a vaccine that would enable infected animals to be
distinguished from vaccinated ones (DIVA vaccine), we have evaluated the immunogenicity of recombinant fowlpox
(FP) and replication-defective recombinant human adenovirus 5 (Ad), expressing PPRV F and H proteins, in goats.
The Ad constructs induced higher levels of virus-specific and neutralising antibodies, and primed greater numbers
of CD8+ T cells than the FP-vectored vaccines. Importantly, a single dose of Ad-H, with or without the addition of
Ad expressing ovine granulocyte macrophage colony-stimulating factor and/or ovine interleukin-2, not only induced
strong antibody and cell-mediated immunity but also completely protected goats against challenge with virulent
PPRV, 4 months after vaccination. Replication-defective Ad-H therefore offers the possibility of an effective DIVA
vaccine.Introduction
Peste des petits ruminants virus (PPRV) causes a devas-
tating disease in goats with mortality rates reaching 70%
and higher depending on the virus isolate and health of
the animals. The virus is widespread throughout Africa,
Asia and the Middle East. Clinical signs of disease in-
clude leukopenia, pyrexia, congestion of mucosal sur-
faces, severe ocular and nasal discharge, necrotic
stomatitis, diarrhoea and suppression of the immune
system often leading to co-infections. Currently, live at-
tenuated PPRV vaccines are available and can protect
animals from subsequent infection. However, these vac-
cines are not thermostable, requiring a cold chain for
delivery to the field which is an added issue, as countries* Correspondence: geraldine.taylor@pirbright.ac.uk
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unless otherwise stated.most affected by the disease are hot and often have lim-
ited infrastructure. While work is in progress in other
labs to improve the thermostability of lyophilised PPRV
preparations, development of an intrinsically more ther-
motolerant vaccine, such as poxvirus- or adenovirus-
vectored vaccines would be beneficial. Vaccinated ani-
mals produce high levels of neutralizing antibodies
against the haemaglutinin (H) and fusion (F) proteins as
well as non-neutralizing antibodies against the nucleo-
capsid protein (N), similar to that seen in animals that
have recovered from natural infection [1]. These vac-
cines do not allow infected-recovered animals to be dis-
tinguished from vaccinated animals. A vaccine that
allows differentiation of infected from vaccinated ani-
mals (DIVA) would be of value in PPRV control pro-
grammes as well as a PPRV eradication campaign.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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munity against PPRV could be elicited by expression of
just the viral glycoproteins. Recombinant vaccinia virus
expressing F and H proteins of rinderpest virus (RPV),
which is a close relative of PPRV, protected goats against
PPRV challenge, although it did not induce PPRV-
specific neutralising antibodies [2]. Similarly, recombin-
ant capripox viruses expressing F and H proteins from
RPV [3], or PPRV H or F have been shown to protect
goats against PPR [4]. We have sought to evaluate two
alternative vectors for expression of the PPRV H and F
glycoproteins, fowlpox virus (FP) and replication-
defective human adenovirus type 5 (Ad). Recombinant
FP-based vaccines have been proven to be effective when
used in mammals, despite their inability to replicate in
mammalian cells [5,6]. Replication-defective adenovirus
vectors have been shown to be a promising platform for
delivery of vaccine antigens in a number of species. Al-
though many conventional vaccines are based on induc-
tion of protective antibodies, it is clear that, for many
pathogens, induction of CD8+ T-cell responses are crit-
ical for rapid clearance of the pathogen [7]. Vaccination
with Ad vectors have been shown to elicit better CD8+
T-cell responses compared with poxvirus vectors [8].
The CD8+ T-cell response elicited by Ad5 is predomin-
antly an effector memory phenotype [9]. Ad5 induces a
CD8+ T-cell response with a protracted contraction
phase and sustained memory population [10-12]. Ad-
based vaccines have shown promise as a single dose vac-
cine in mice against respiratory syncytial virus [13],
Mycobacterium tuberculosis [14] and measles virus [15].
If such recombinant viruses are to be useful as field vac-
cines against PPR, it will be important that they are effect-
ive after a single dose, since the main cost in large scale
vaccination campaigns is taken up by distribution and ad-
ministration of vaccines. We have therefore investigated
the possible adjuvant properties of virus-vectored delivery
of cytokines, granulocyte macrophage colony stimulating
factor (GMCSF) and interleukin-2 (IL-2). GMSCF is a cyto-
kine important for recruitment, activation and maturation
of antigen-presenting cells [16]. In a number of DNA vac-
cine studies, GMCSF has been shown to have adjuvant
properties [17-21]. Furthermore, GMCSF expressed by re-
combinant FP has been shown to enhance CTL responses
in mice compared to vaccination with antigen and recom-
binant GMCSF protein [22]. However, other groups have
found that GMCSF did not enhance CD8+ T-cell or anti-
body responses [23-25]. IL-2 is involved in activation and
recruitment of immune effector cells such as T cells, NK
cells, B cells and antigen-presenting cells [26,27]. Co-
delivery of IL-2 with DNA vaccination has been shown to
enhance antibody responses and increase protection in a
variety of animal species [28-30]. Furthermore, IL-2 in
combination with GMCSF has been shown to enhanceCTL and memory responses [31,32] and act in combination
to have an increased adjuvant effect [33,34]. In a number of
other animal diseases, addition of IL-2 and GMCSF to vac-
cines has shown promise as potential adjuvants [35,36]. We
have investigated FP and Ad recombinants as vaccine vec-
tors to deliver PPRV surface glycoproteins to small rumi-
nants. The addition of vectors expressing ovine IL-2 and
GMCSF was also investigated. We have shown that a single
dose of Ad expressing PPRV H glycoprotein is sufficient to
protect goats from PPRV challenge and that the addition of
IL-2 may contribute to induction of sterile immunity.
Materials and methods
Vaccines
Recombinant FP virus and recombinant Ad virus ex-
pressing ovine IL-2, ovine GMCSF, PPRV H or PPRV F
protein, as well as control adenovirus constructs ex-
pressing GFP (Ad-GFP) [37] or an irrelevant antigen
(Ag85) (Ad-85) [38] were produced by the Vector Core
Facility, Jenner Institute, Oxford, using Fowlpox 9 [39]
and E1, E3 deleted human Adenovirus type 5 (Vira-
power, Life Technologies) vectors. PPRV F and H coding
sequences were derived from the attenuated Nigeria75/1
PPRV vaccine strain [40] and have been previously pub-
lished [41]. The plasmids OvIL-2/pGEM-T-Easy and
OvGM-CSF/pGEM-T-Easy were the gift of Gary Entri-
can, Moredun Institute, Edinburgh. Titres of recombin-
ant FP virus stocks ranged from 2 × 108 to 1 × 109 PFU/
mL, and titres of recombinant Ad virus stocks ranged
from 1 × 1010 to 2 × 1011 IU/mL.
Cells
Human embryonic kidney (HEK 293) cells were ob-
tained from ECACC (European Collection of Cell Cul-
tures, catalogue No: 85120602) and cultured in D-MEM
containing 10% foetal calf serum (FCS), 100 units/mL
penicillin, 100 units/mL streptomycin and 50 μg/mL Ny-
statin (DMEM complete). Chicken embryonic fibroblast
cells (CEFs) were prepared by the Microbiological Ser-
vices department at the Pirbright Institute, Compton
site, from 9 day-old Rhode Island Red embryos obtained
from the poultry production unit at the institute.
Peptides
PPRV F and H specific peptides were synthesised by
Mimotopes, Ltd. Peptides were designed against the
whole protein sequence of each protein and consisted of
15mer peptides, overlapping by 10 amino acids. Peptides
were dissolved in DMSO.
Characterisation of the Ad and FP constructs
For analysis of the expression of PPRV proteins, HEK
293 cells were infected with Ad-F, Ad-H or Ad-GMCSF
in 6 well plates for several days until cpe was starting to
Table 1 Vaccine groups for challenge study
Group No goats Ad-GFP Ad-H Ad-IL-2 Ad-GMCSF
A 4 1 × 109 IU - 1 × 109 IU 1 × 109 IU
B 3 2 × 109 IU 1 × 109 IU - -
C 3 1 × 109 IU 1 × 109 IU 1 × 109 IU -
D 3 1 × 109 IU 1 × 109 IU - 1 × 109 IU
E 3 - 1 × 109 IU 1 × 109 IU 1 × 109 IU
16 outbred, European, male goats, 9 to 12 months of age were vaccinated
intra-muscularly with a total of 3 × 109 IU of recombinant adenovirus per
animal in a final volume of 1 mL PBS.
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western blot analysis carried out using an anti-PPRV F
monoclonal antibody designed in our laboratory or
rabbit polyclonal antibody raised to purified PPRV H
(the kind gift of Prof M.S. Shaila, Indian Institute of Sci-
ence, Bangalore). Parallel samples were analysed using
Vero-SLAM cells infected with PPRV. For assays of
cytokine expression, HEK 293 cells were infected at a
multiplicity of infection (MOI) of 10 in 6 well plates.
Virus was allowed to adsorb for 2 h before replacing the
inoculum with 2 mL of fresh medium and culturing
overnight at 37 °C. The tissue culture supernatants
(SNs) were harvested from each well and cell lysates
(CLs) were prepared by scraping the cells into 500 μL of
sterile water. Chicken embryonic fibroblasts (CEF) were
infected with recombinant FP at a MOI of 5 in 6 well
plates for 2 h before replacing the inoculum with fresh
medium and leaving the cells overnight at 37 °C. CLs
and SNs were harvested and stored at -20 °C before ana-
lysis of the functional activity of IL-2 and GMCSF pro-
duced from infected cells.
GMCSF activity was analysed by measuring the ability
of SNs and CLs from Ad- or FP-infected cells to induce
proliferation of bone marrow cells. Bone marrow cells
were prepared from a fresh goat metacarpal bone. Tissue
was rotated in PBS containing 5 mM EDTA at room
temperature for one hour to extract cells. The cell sus-
pension was passed first through sterile muslin and then
a 70 μm cell strainer before centrifugation for 8 min at
500 × g at 4 °C to pellet cells. Contaminating red cells
were lysed in ammonium chloride lysis buffer (0.8%
NH4Cl, 0.1 mM EDTA) and the bone marrow cells
washed three times in PBS before re-suspending in
RPMI/10 containing 10% goat serum (GS), 5 × 10-5 M 2-
mercaptoethanol, 100 units/mL penicillin, 100 units/mL
streptomycin and 50 μg/mL Nystatin (RPMI complete).
Duplicate, 2-fold dilutions of CLs or SNs were incubated
with 1 × 105 bone marrow cells per microtitre well.
Plates were incubated for 6 days at 37 °C with 5% CO2
and then labelled overnight with [3H]-thymidine. The
lymphocyte proliferative responses were expressed as the
ratio of cpm in cultures stimulated with CLs or SNs
from virus-infected cells to that of cultures stimulated
with CLs and SNs from non-infected cells and expressed
as a stimulation index (S.I.). The S.I. for CLs and SNs
was combined.
IL-2 activity was analysed by measuring the ability of
SNs and CLs from Ad- or FP-infected cells to induce the
proliferation of peripheral blood lymphocytes. Duplicate,
2-fold dilutions of CLs or SNs were incubated with
heparinised goat blood for 6 days before labelling over-
night with [3H]-thymidine. The lymphocyte proliferative
responses were expressed as the ratio of cpm in cultures
stimulated with CLs or SNs from virus-infected cells tothat of cultures stimulated with CLs and SNs from non-
infected cells and expressed as the S.I.
Goats and experimental design
Male goats, aged between 6 months and 1 year were
sourced locally. All were of European breeds, but were
of mixed breeds. All animal studies were carried out in
accordance with UK Home Office regulations and under
the supervision of the local Ethical Committee. Animals
were vaccinated intra-muscularly in the left shoulder
with vaccine made up to 1 mL with sterile PBS. The
doses of recombinant virus vectors used to vaccinate
goats were similar to those that had previously been
used in man and goats [39,42].
Experiment 1:
One animal was vaccinated with a mixture of 1 × 109 IU
Ad-F and 1 × 109 IU Ad-H and the other goat was vacci-
nated with a mixture of 1 × 108 PFU FP-F and 1 × 108
PFU FP-H. Blood was taken weekly for sera and prepar-
ation of peripheral blood mononuclear cells (PBMC).
Animals were given an homologous boost, 5 weeks later,
and were killed 8 weeks post vaccination by intravenous
pentobarbitone overdose. At post mortem examination,
pre-scapular lymph nodes (PLN) were removed for ana-
lysis of H- and F-specific T-cell responses.
Experiment 2:
Four goats were vaccinated with a mixture of 1 × 109 IU
Ad-F and 1 × 109 IFU Ad-H and four goats were vacci-
nated with a mixture of 1 × 108 PFU FP-F and 1 × 108
PFU FP-H. Two animals from each group were also vac-
cinated with a mixture of 1 × 109 IU Ad-IL-2 and 1 ×
109 IU Ad-GMCSF or a mixture of 1 × 108 PFU FP-IL-2
and 1 × 108 PFU FP-GMCSF respectively. Blood was
taken weekly for sera and preparation of PBMC, and an-
imals were killed 12 weeks post vaccination by intraven-
ous pentobarbitone overdose. At post mortem
examination, PLN were removed.
Experiment 3:
Goats were vaccinated as shown in Table 1 with a total
of 3 × 109 IU of recombinant Ad per animal. Blood was
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were challenged intranasally 15 weeks after vaccination
with 1 × 105 TCID50 of pathogenic PPRV (Ivory Coast/
89 isolate). The rectal temperature was measured daily,
and an average of the values from day -3 to day 0 of
challenge were taken as the basal body temperature for
each animal. Clinical assessments were carried out daily
and animals scored on a scale from 0 to 2 or 3, based on
the severity of ocular, oral and nasal congestion and dis-
charge as well as signs of apathy, anorexia, diarrhoea
and ulceration in the mouth, as shown in Table 2. The
scores were combined to give an overall clinical score
for each day post challenge (pc). Nasal, oral and ocular
swabs were taken on day 0, 4 to 8, 11 and 14 pc for ana-
lysis of PPRV by quantitative RT-PCR (see below). Nasal
swabs taken on day 4, 6, 7 and 10 were also analysed for
virus by isolation/titration (VI). Blood was taken in
EDTA on days 0, 4, 7, 11 and 14 pc for analysis of white
cell counts and viraemia by RT-PCR. Heparinised blood
was taken at day 6 pc for preparation of PBMC. Animals
were killed by intravenous pentobarbitone overdose ei-
ther at day 14 pc or earlier if they had reached the hu-
mane end point determined by the Home Office project
licence.
Nasal swabs were washed in medium (DMEM containing
10% FCS, 100 units/mL penicillin, 100 units/mL strepto-
mycin) to extract virus from the swabs and then serial dilu-
tions were plated with VDS cells in at least quadruplicate,
starting with a 1 in 10 dilution, for determination of virus
titre by TCID50. Alternatively, a 1 in 6 dilution of the sam-
ple was used to inoculate VDS cells for virus isolation (VI).
Infected cells were cultured for up to 7 days at 37 °C with
5% CO2. Wells were scored for the presence of cpe.
Blood samples and swabs taken after PPRV challenge
were analysed by reverse transcription-real time PCR
[43] to determine the level of viraemia and virus in nasal
secretions. RNA was extracted from EDTA blood or
swabs, reverse transcribed and amplified with Super-
Script® III Platinum® One-Step qRT-PCR w/ROX Kit,
(Invitrogen™). Primer 5’-3’sequences were, PPRVFOR:-
AGAGTTCAATATGTTRTTAGCCTCCAT;Table 2 Clinical scores
Clinical signs 0 1
Temperature ≤ Initial + 0.1 Initial + 0.1 to ≤ initia
Nasal signs None Congestion
Ocular signs None Congestion
Oral signs None Congestion gums/pa
Diarrhoea None Diarrhoea
Respiration Normal Coughing
Behaviour Normal ApatheticPPRVREV:- TTCCCCARTCACTCTYCTTTGT;
probe: FAM-CACCGGAYACKGCAGCTGACTCA-
GAA – Tamra.
Primers were used at 10 pmol/μL and the probe at 5
pmol/μL. The thermal profile was 50 °C for 30 min, 95 °C
for 10 min, then 45 cycles of 95 °C for 15 s followed by
60 °C for 1 min.Isolation of PBMCs and lymph node cells
PBMC were prepared from heparinised venous blood by
centrifugation at 1200 g over Histopaque 1083 (Sigma-
Aldrich, Inc.) for 45 min at 20 °C. Cells were washed
three times in PBS before re-suspension in RPMI/10
complete medium. Pieces of lymph node were pushed
gently through a sterile, metal tea strainer into a petri
dish containing PBS, 200 units/mL penicillin, 200 units/
mL streptomycin and 100 μg/mL Nystatin. The cell sus-
pension in PBS was further filtered through a 100 μm
cell strainer, and cells were purified on histopaque gradi-
ents as described above for PBMCs and then cultured in
RPMI/10 complete medium. Spare cells were also frozen
in FCS with 10% DMSO.Serology
Serum antibodies specific for the PPRV H glycoprotein
were analysed by competition ELISA (cELISA) using a
PPR Antibody ELISA kit (BDSL). Antibodies specific for
the PPRV N protein were detected by cELISA using the
ID Screen PPR Competition kit (ID Vet).
PPRV neutralising antibodies were analysed essentially
as described in the OIE manual, chapter 2.7.11, section
3a. Sera was heat inactivated at 56 °C for 30 min and
serially diluted two-fold in quadruplicate. PPRV Nigeria
75/1 was diluted in media to give 100-150 infectious
units/50 μL and incubated with the diluted serum at
37 °C in 5% CO2 for one hour. Vero-dog-SLAM (VDS)
cells were added to the virus/serum mixture at 1 × 105
cells per microtitre well. Plates were incubated for one
week and then scored for the presence or absence of cy-
topathic effect. The neutralising titre was the reciprocal2 3
l + 2 > Iinitial + 2
Discharge
Discharge
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50% of infected wells. Neutralising titres were calculated
using the Spearman-Kärber equation to determine
TCID50.Lymphocyte assays
PBMCs were stimulated with either peptide pools, at
final concentration of 10 μg/mL, or with Ad or FP
viruses. Stimulation with Ad was at a MOI of 100 virus
particles and FP at a MOI of 0.1 PFU. Concanavalin A
was used as a positive control at a final concentration of
25 μg/mL. All assays were performed in triplicate. The
lymphocyte proliferative responses were expressed as the
ratio of counts incorporated in cultures stimulated with
peptide to counts incorporated in cultures with media
containing DMSO at the same concentration as the pep-
tides, or the ratio of counts in cultures stimulated with
Ad or FP expressing PPRV antigens to counts in cells
stimulated with a corresponding virus expressing an ir-
relevant antigen. Data is expressed as the S.I., and an S.I.
greater than 5 was considered to be significant.
PBMCs and lymphocytes from the PLN were stimu-
lated with peptide pools, or Ad or FP viruses as de-
scribed above for 24 h and brefeldin A was added for
the last 4 h of culture. Live cells were stained using live/
dead aqua (Molecular probes®), and monoclonal anti-
bodies (mAbs) to surface markers CD4 conjugated to
allophycocanin (APC) (clone 44.38, MCA2213A647
from Serotec) and CD8 conjugated to R-Phycoerythrin
(RPE) (clone CC63, MCA837 from Serotec). Cells were
permeabilised with BD FACS permeabilisation buffer
and stained with mAb to IFNγ (clone CC327, MCA2334
from Serotec). Cells were analysed using the LSR For-
tessa (BD Biosciences). The DIVA software was used to
acquire the data and FCS Express 3 (De Novo Software)
or FlowJo (Tree Star Inc.) used for analysis. The PPRV-
specific response was calculated as the percentage of
IFNγ+ -producing cells after stimulation with Ad or FP
constructs expressing the PPRV protein minus the per-
centage of such cells after stimulation with Ad or FP ex-
pressing an irrelevant antigen.
At day 0, 4 and 7 pc with PPRV, heparinised blood
was stained with antibodies for surface markers CD4,
CD8, using antibodies described above, annexin V anti-
body conjugated to FITC (Aposcreen kit, SouthernBio-
tech), CD14 (clone CCG33) antibody conjugated to R-
PE and antibody to WC1, a marker for γδ T cells (clone
197), conjugated to APC using a Zenon® kit (Life Tech-
nologies). Red blood cells were lysed using BD FACS
lysis solution. Cells were fixed in 4% PFA and permeabi-
lised as above. Intracellular virus was detected using the
anti-PPRV H monoclonal antibody C77 conjugated to
Alexa Fluor-405 using a Zenon® kit (Life Technologies).Results
Characterisation of Ad and FP vaccine vectors expressing
PPR glycoproteins, ovine IL-2 or ovine GMCSF
Recombinant viruses were analysed to confirm expres-
sion of the PPRV F and H proteins and expression of
biologically active IL-2 and GMCSF. CEF cells were
infected with FP expressing F or H and the expressed
proteins were visualised by confocal microscopy using
H- and F-specific mAbs. Clear, specific staining was ob-
served in cells infected with FP-F and FP-H (data not
shown). For the Ad recombinants, lysates of HEK 293
cells infected with Ad-F, Ad-H and Ad-GMCSF (as
negative control) were analysed by Western blotting to
detect the expression of the PPRV proteins (Figure 1A).
Bands corresponding to PPRV F (≈ 46 kDa) or H (≈
80 kDa) proteins were detected, although the H protein
appeared to be susceptible to partial degradation in the
HEK293 cells when expressed on its own (Figure 1A).
The production of biologically active GMCSF by the
recombinant vaccine vectors was confirmed by the find-
ing that CLs and SNs from cells infected with Ad-
GMCSF (Figure 1B) or FP-GMSCF (data not shown),
but not from mock-infected, Ad-H or FP-H-infected
cells, induced the proliferation of goat bone marrow
cells. The production of biologically active IL-2 was con-
firmed by the finding that SNs from Ad-IL-2 (Figure 1C)
or FP-IL-2-infected cells (data not shown), but not
mock-, Ad-H or FP-H infected cells induced prolifera-
tion of goat lymphocytes.
Immune responses induced in goats vaccinated with Ad
or FP expressing PPRV glycoproteins
In order to determine the ability of FP or Ad constructs
to elicit PPRV-specific immune responses in goats, pre-
liminary experiments were carried out using 2 animals
(experiment 1). The animal vaccinated with Ad-F plus
Ad-H showed an increase in PPRV-neutralising antibody
titre from week 1 to week 3 post vaccination after which
the antibody levels plateaued until boosting at week 5
(Figure 2A). After boosting, the neutralising antibodies
increased rapidly. In contrast, neutralising antibodies
were not detected in the FP-vaccinated goat prior to
boosting, and even after boosting antibody levels were
low (Figure 2A). Lymphocyte proliferation and IFNγ
ELISpot assays were carried out using PBMC re-
stimulated with Ad or FP expressing H, F or an
irrelevant antigen. However, the data were inconclusive.
At post mortem examination, 3 weeks after boosting,
PLN lymphocytes were stimulated with Ad-F, Ad-H
(Figure 2C), control AdV, Ad-85 (Figure 2D), FP-F, FP-H
or FP control virus, and analysed by flow cytometry to
identify IFNγ-producing CD4+ and CD8+ T-cells. The
percentage of PPRV F/H-specific IFNγ-producing CD8+






































































































Figure 1 Expression of PPRV glycoproteins and functionally active ovine IL-2 and GMCSF, in vitro. (A) HEK 293 cells were infected with
Ad-F, Ad-H or Ad-GMCSF, and Vero-SLAM cells were infected with PPRV or mock infected. Total cell lysates were analysed by Western blot using
an anti-PPRV F monoclonal antibody or polyclonal rabbit anti-PPRV H serum as indicated. (B, C) HEK 293 cells were infected with Ad-IL-2,
Ad-GMCSF or Ad-H, or mock infected overnight and cell lysates (CLs) and supernatants (SNs) were harvested. The biological activity of GMCSF in
CLs and SNs combined from Ad-GMCSF, Ad-H or mock-infected cells was determined by analysis of proliferation of goat bone marrow cells. The
biological activity of IL-2 in SNs from Ad-IL-2, Ad-H or mock-infected cells was determined by analysis of proliferation of goat blood lymphocytes.
Proliferation was measured by 3H-thymidine incorporation after 7 days incubation and expressed as the mean stimulation index ± S.D. of
triplicate wells.
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IFNγ-producing CD4+ cells were not detected in PLNs
from either the Ad- or FP-vaccinated goat. Although
only one goat was vaccinated with Ad or FP virus vec-
tors, it was clear that vaccination induced an immune
response to the expressed PPRV F and H proteins, and
so a larger study was carried out to compare single doses
of Ad and FP, and to examine the ability of virus-
vectored administration of GMCSF and IL-2 to enhance
the immune response.
Effect of virus-vectored ovine IL-2 and GMCSF on immune
responses induced in goats vaccinated with Ad or FP
constructs expressing PPRV glycoproteins
In order to confirm that Ad vaccination induced a better
immune response than FP vaccination and to analyse theadjuvant effects of virus-vectored GMCSF and IL-2, groups
of two goats were vaccinated as described in Materials and
Methods for experiment 2. Lymphocyte proliferation in re-
sponse to PPRV H or F proteins at week 0 and 4 post vac-
cination was analysed following stimulation with pools of
PPRV F or H peptides. The responses have been combined
for all the Ad-vaccinated animals and for all the FP-
vaccinated animals as there was no significant effect of
virus-vectored IL-2 plus GMCSF on the lymphocyte prolif-
erative response. At 4 weeks post vaccination, F- and
H-specific T-cell responses were only detected in the Ad-
vaccinated animals (Figure 3A). In order to further charac-
terise the T-cell mediated immune response induced by the
vaccines, PLN lymphocytes, obtained 12 weeks after vaccin-
ation, were stimulated with H peptide pools and analysed

















































Figure 2 Immune responses induced in goats vaccinated with Ad or FP expressing PPRV glycoproteins. One goat was vaccinated
intra-muscularly with a mixture of 1 × 109 IU of Ad-H and 1 × 109 IU Ad-F and another goat was vaccinated intra-muscularly with a mixture of
1 × 108 pfu of FP-H and 1 × 108 pfu FP-F. Goats were boosted intra-muscularly with the same doses of the respective vaccines, 5 weeks later. (A)
Neutralising antibody titres were determined by 50% plaque reduction assay. (B) At post mortem examination, 9 weeks after vaccination, F- and
H-specific T-cell responses in prescapular lymph nodes were analysed by flow cytometry of lymphocytes stimulated with Ad-H, Ad-F, FP-H, FP-F
or control Ad and FP expressing an irrelevant antigen. Cells were stained for CD8 and intracellular IFNγ. Results are expressed as the percentage
of CD8+ IFNγ+ T-cells following stimulation with virus vector expressing F or H minus percentage following stimulation with control virus vectors.
Dot plot showing CD8+ IFNγ+ T-cells from the prescapular lymph node from the Ad-vaccinated goat after stimulation with Ad-H (C) and after
stimulation with Ad expressing an irrelevant antigen (D).
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were slightly greater in the animals also vaccinated with
virus-vectored IL-2 and GMCSF (Figure 3B). A low level of
H-specific CD4+ IFNγ+ cells were detected in PLN from 2
out of 4 Ad-vaccinated goats (Figure 3B). H-specific CD8+
IFNγ+ cells were also detected in PLN from all FP-
vaccinated goats. However, the frequency of CD8+ IFNγ+
cells in 2 of the goats was lower than that seen in the Ad-
vaccinated animals (Figure 3B). H-specific CD4+ IFNγ+
cells were not detected in PLN from FP-vaccinated animals.
From week 2 post-vaccination to week 12, sera from
Ad-vaccinated animals showed a significantly greater in-
hibition of binding of an H-specific mAb to PPRV anti-
gen than sera from FP-vaccinated animals (p < 0.0001;
2-way ANOVA) (Figure 3C). Furthermore, the average
percentage inhibition by sera from the Ad-vaccinated
animals that had also been given Ad-IL-2 and Ad-
GMCSF, was significantly greater than the average of the
two goats vaccinated with Ad-F and Ad-H only (p < 0.05),
from week 4 post vaccination to week 12. PPRV-specific
neutralising antibodies were not detected in any FP-vaccinated animals (Figure 3D). In contrast, all Ad-
vaccinated animals developed neutralising antibodies
from week 2 post vaccination, which reached a peak be-
tween 2 to 5 weeks after vaccination, and then gradually
declined, although 3 out of 4 goats still had neutralising
antibody titres > log10 1.0 at 12 weeks after a single
vaccination with Ad-vectored vaccines. One goat,
which was also vaccinated with Ad-IL-2 plus Ad-
GMCSF, had very high levels of neutralising antibodies
which peaked 5 weeks after vaccination and remained
high at 12 weeks post vaccination.
Adenovirus vaccination protects against challenge with
PPRV
Since the major T-cell responses in the Ad-vaccinated
animals appeared to be directed to the H protein, and
neutralising antibodies are mainly induced by the H pro-
tein [1], we tested the ability of this construct to protect
against challenge with virulent PPRV. Goats were vacci-
nated with recombinant Ad viruses as described in









Ad Ad Ad++Ad++ FP FP FP++FP++




















































































Ad vacc  vacc
Figure 3 Effect of virus-vectored ovine IL-2 and GMCSF on immune responses induced in goats vaccinated with Ad or FP expressing
PPRV glycoproteins. Groups of two goats were vaccinated intra-muscularly with a mixture of 1 × 109 IU of Ad-F and 1 × 109 IU of Ad-H with or
without the addition of 1 × 109 IU of Ad-IL-2 and 1 × 109 IU of Ad-GMCSF (Ad++), or with a mixture of 1 × 108 pfu FP-F and 1 × 108 pfu FP-H, with
or without the addition of 1 × 108 pfu FP-IL-2 and 1 × 108 pfu FP-GMCSF (FP++). (A) Priming of F- and H-specific T-cells was determined by
proliferation of PBMCs stimulated, in vitro, with peptide pools representing the PPRV F and H proteins. Results are expressed as the mean
stimulation index ± S.E for all the Ad-vaccinated or all the FP-vaccinated animals. (B) At post mortem examination, 12 weeks after vaccination,
H-specific T-cells in prescapular lymph nodes were analysed by flow cytometry of lymphocytes stimulated, in vitro, with H peptides. Results are
expressed as % CD4+ IFNγ+ and CD8+ IFNγ+ from each animal. (C) H-specific serum antibody responses were determined by competition ELISA
and expressed as % inhibition of the binding of an H-specific monoclonal antibody to PPRV. (D) Virus neutralising antibodies were analysed as
described in methods and expressed as Log10 neutralising titre.
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later. Following vaccination and after challenge, H-
specific T-cell proliferation responses were analysed after
stimulation of PBMCs with H protein peptides. At
2 weeks post vaccination, H peptide-specific T-cell pro-
liferative responses were observed in goats vaccinated
with Ad-H + Ad-IL-2 and animals vaccinated with Ad-H
+ Ad-GMCSF, but not in goats in the other vaccine
groups (Figure 4A). At 4 weeks post vaccination, H
peptide-specific T-cell proliferative responses were only
seen in animals vaccinated with Ad-H + Ad-GMCSF.
There was considerable variation between animals as in-
dicated by the error bars.
PPRV H-specific IFNγ-producing CD8+ cells were de-
tected in all Ad-vaccinated goats 3 weeks after vaccin-
ation and the proportion of these cells was highest in
animals also vaccinated with Ad-GMCSF (Figure 4B).
The proportion of H-specific CD8+ IFNγ+ cells at the
time of PPRV challenge (week 15) was low and similar
to that seen prior to vaccination. However one week
after challenge, an increase in H-specific IFNγ producing
CD8+ cells was observed in all the vaccinated animals
except the Ad-H + Ad-GMCSF group. In contrast, H-
specific IFNγ-producing CD4+ T-cells were seen only at
very low levels throughout the study, although there wasa slight increase in the proportion of CD4+ IFNγ+ cells
in Ad-H + Ad-IL-2 vaccinated animals one week after
challenge (Figure 4C). As seen previously, Ad vaccin-
ation was more effective at priming CD8+ cells than
CD4+ cells.
By week 2 post vaccination, H-specific serum anti-
bodies were detected by cELISA in all the Ad5-H vacci-
nated animals (Figure 5A). There was little difference in
the ability of sera from the Ad-H vaccinated groups to
inhibit the binding of the H-specific mAb to PPRV.
After challenge, H-specific serum antibodies increased
rapidly in all animals. PPRV neutralising antibodies were
detected in sera from all the Ad-H vaccinated animals
from week 2 post vaccination and remained high until
challenge (Figure 5B). After challenge, there was a corre-
sponding sharp increase in the level of neutralising anti-
bodies in all Ad-H and control vaccinated animals. H-
specific (cELISA-reactive) and neutralising antibodies
were not detected in the control vaccine group prior to
challenge. The vaccine group which received Ad-H and
Ad-IL-2 had slightly higher levels of neutralising anti-
bodies and H-specific antibodies than the other vaccine
groups. However, the differences were small.
In order to assess the potential of Ad-H as a DIVA
















































































Figure 4 Effect of virus-vectored ovine IL-2 and/or GMCSF on
T-cell responses induced in goats vaccinated with Ad expressing
the H protein of PPRV. Goats were vaccinated intra-muscularly
with 1 × 109 IU of each Ad virus as described in Table 1 and were
challenged intranasally with 1 × 105 TCID50 of pathogenic PPRV, Ivory
Coast/89, 15 weeks later. PBMCs were stimulated with H peptides
and H-specific T-cell proliferative responses were measured by
3H-thymidine incorporation (A); and H-specific CD8+ IFNγ+ (B) and
CD4+ IFNγ+ (C) cells were analysed by flow cytometry. Results are
expressed as the mean stimulation index or mean % IFNγ-containing
cells ± S.E. of 3 to 4 goats.
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before and after challenge with PPRV. As expected, none
of the animals had N-specific antibodies before chal-
lenge. However, N-specific antibodies were detected
from day 7 pc in the controls (Figure 5C). N-specific
antibodies were slower to develop in the Ad5-H vaccine
groups and were first detected at days 11 and 14 pc.
Analysis of the level of N-specific antibodies suggested
that they were significantly lower in goats vaccinated
with Ad-H plus Ad-IL-2 (P < 0.001). Ad-GMCSF did
not appear to have an effect on induction of N-specific
antibodies after challenge.
Vaccination with Ad-H induced complete protection
against challenge with virulent PPRV. Following PPRV
challenge, there was a rapid decline in blood leucocytesin the control goats, characteristic of PPRV infection,
which was not observed in any of the Ad-H vaccinated
groups (Figure 6A). White cell counts did not recover in
the surviving control animal before the end of the study.
All animals in the control vaccine group developed an
increase in temperature by day 4 pc (Figure 6B). A
slightly elevated body temperature was seen in goats
vaccinated with Ad-H + Ad-GMCSF from day 5 to day 8
pc. However, the temperatures of these animals varied
even prior to challenge, and the peak temperature (at
day 6) was not significantly higher than that seen at day
1 pc. The body temperatures of the other Ad-H vacci-
nated groups remained fairly constant following PPRV
challenge (Figure 6B). The goats in the control group
were the only animals which exhibited any significant
signs of clinical disease, and 3 out of 4 animals had to be
euthanized prior to the end of the experiment as they
had reached the permitted humane end-point for the
study (Figure 6C). A number of Ad-H vaccinated goats
had a slight redness around the nose and eyes but this
may have been due to other factors not associated with
PPRV challenge, such as swabbing. Virus RNA was de-
tected in blood (Figure 6D) and virus was isolated from
the nasopharynx (Table 3) and ocular swabs (data not
shown) from all control animals at day 7 pc. In addition,
virus was isolated from nasal swabs on day 6 and 10 pc
in some of the control animals (data not shown). In con-
trast, viral genome was not detected in the blood, and
live virus was not isolated from nasopharyngeal swabs of
any of the Ad-H vaccinated animals (Figure 6D and
Table 3).
The effect of PPRV infection of the proportion of
lymphocyte subsets in peripheral blood was also ana-
lysed by flow cytometry. The proportion of live CD4+
cells decreased at day 4 pc in the control group by about
10% (Figure 7A). This decrease was associated with an
increase in dead CD4+ cells at this time point (data not
shown). At day 7 pc, there was an increase in live CD8+
cells (Figure 7B) and also dead CD8+ cells (data not
shown). There was no change in the percentage of live
γδ-T cells (data not shown) or CD14+ monocyte/macro-
phage cells (Figure 7C). Intracellular PPRV H protein
was only detected in live CD4+ (Figure 7D) and CD8+
(Figure 7E) cells at day 4 pc. Intracellular H protein was
detected in 4% of CD4+ cells from control vaccinated
animals, which was greater than that detected in Ad-H-
vaccinated goats. However, there was considerable vari-
ation in the proportion of CD4+ cells with intracellular
H protein in these animals. The proportion of CD8+
cells with intracellular H protein was less than that of
CD4+ cells. There was little or no detectable intracellular
H protein in either CD4+ or CD8+ cells from Ad-H vac-
cinated animals which had also received GMCSF. The




































































Figure 5 Effect of virus-vectored ovine IL-2 and/or GMCSF on serum antibody responses induced in goats vaccinated with Ad
expressing the H protein of PPRV. Goats were vaccinated intra-muscularly with 1 × 109 IU of each Ad virus as described in Table 1 and were
challenged intranasally with 1 × 105 TCID50 of pathogenic PPRV, Ivory Coast/89, 15 weeks later. Mock refers to group A of Table 1 (Ad-GFP +
Ad-IL-2 + Ad-GMCSF), while H++ refers to group E of Table 1 (Ad-H + Ad-IL-2 + Ad-GMCSF). (A) H-specific serum antibody responses were analysed
by competition ELISA and expressed as mean % inhibition of the binding of an H-specific monoclonal antibody to PPRV ± S.D. (B) Virus
neutralising antibody titres were determined by 50% plaque reduction assay and expressed as log10 neutralising titre ± S.D. (C) The N-specific
serum antibody response was analysed by ELISA and the post-challenge (pc) response is expressed as mean % inhibition of the binding of a PPRV
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Figure 6 Vaccination with Ad-H protects against PPRV challenge. Goats were vaccinated as described in Table 1 and challenged with PPRV
as described in Figure 4. Mock refers to group A of Table 1 (GFP + IL-2 + GMCSF), while H++ refers to group E of Table 1 (H + IL-2 + GMCSF). (A)
Changes in the number of blood leukocytes were determined daily after challenge and results are expressed as a % of day 0 value ± S.E. (B)
Rectal temperatures were obtained daily and expressed mean body temperature ± S.E. (C) Signs of clinical disease were assessed daily and
animals given a score based on the severity of congestion in the mucosa of the eyes, nose and gums, ocular and nasal discharge, temperature,
diarrhoea, necrotic stomatitis and general malaise. Results are expressed as the mean score ± S.E. (D) Viremia was determined by qPCR and
expressed as the mean 40 - ct value ± S.E.
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Table 3 PPRV in the nasopharynx 7 days post challenge (pc)
Vaccinea Mean PPRV titre in nasopharynx (log10 TCDI50/mL)
b
Ad-GFP + Ad-IL-2 + Ad-GMCSF 3.88 +/- 0.84 (4/4)c
Ad-H + Ad-GFP < 0.1 (0/3)
Ad-H + Ad-IL-2 < 0.1 (0/3)
Ad-H + Ad-GMCSF < 0.1 (0/3)
Ad-H + Ad-IL-2 + Ad-GMCSF < 0.1 (0/3)
aGoats were vaccinated as described in Table 1 and challenged with PPRV as described in Figure 3.
bTitres of PPRV in nasal swabs on day 7 pc were analysed on SLAM-Vero cells and results expressed as the mean log10 TCID50/mL.
cNumber of goats from which PPRV was isolated/total on day 7 pc.
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In light of the recent success of the rinderpest eradica-
tion campaign, PPRV would be an excellent candidate
for eradication [44,45] and moves have already been
made towards this. The availability of a DIVA vaccine
would facilitate PPRV sero-surveillance programmes and
speed up the steps leading to disease eradication [46]. In
countries newly affected by PPRV, where sporadic out-
breaks of disease occur and where the disease is not en-
demic, a DIVA vaccine would be of value to prevent
animal movement restrictions being imposed on coun-
tries which cannot prove that animals have been vacci-




























































Figure 7 Effect of virus-vectored ovine IL-2 and/or GMCSF on CD4 an
goats, following PPRV challenge. Goats were vaccinated and challenged
and anti-CD14 monoclonal antibodies directly conjugated to fluorochrome
labelled anti-PPRV H, C77, monoclonal antibody. Results are expressed as th
(B) and CD14+ cells (C) in peripheral blood. The percentage of CD4+ (D) an
presented as the mean percentage ± S.E., 0, 4 and 7 days after PPRV challenall of which are essential for growth, creating a DIVA
version of the current live PPRV vaccines would require
expressing an extra protein from the viral genome (posi-
tively marked vaccine). The alternative is to express one
or two viral proteins from an alternative virus vector,
thereby eliciting immune protection while not inducing
the complete repertoire of antibodies induced following
natural infection or vaccination with a live, attenuated
PPRV vaccine. This was done successfully for RPV using
vaccinia or capripox virus as the vaccine vectors [47-50].
However, these constructs were never used in the field,
in part because they did not offer the same duration of




























d CD8 T-cells and CD14+ monocyte/macrophages in vaccinated
as described in Figure 4. Blood was stained with anti-CD4, anti-CD8
s. Cells were also stained for intracellular virus using fluorochrome-
e mean percentage ± SD of CD4+ lymphocytes (A), CD8+ lymphocytes
d CD8+ (E) lymphocytes with intracellular staining with C77. Data is
ge.
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an explicit requirement for a DIVA vaccine. MVA ex-
pressing PPRV F and H proteins have been shown to
protect goats against subsequent challenge with virulent
PPR but two doses of vaccine were given prior to chal-
lenge [51], which would not be practical for a small ru-
minant vaccination programme. Capripox virus vectors
expressing PPRV glycoproteins have been developed
[4,52]. However, in one case, the ability of the vaccine to
protect against PPRV was not investigated [52], while in
the other, although protection against PPRV was proven
[4], the vaccine has not been used in the field. The posi-
tive aspects of using a recombinant capripox are that it
would simultaneously vaccinate against two serious
sheep/goat diseases; in addition, capripox-based vaccines
would benefit from the intrinsic thermotolerance of pox-
viruses. However, recombinant capripox vaccines may
not be suitable as PPRV DIVA vaccines, as vaccinated
animals did not all give good antibody responses, pos-
sibly due to pre-existing vector immunity. This is im-
portant as it is the comparative antibody response that is
likely to be used as the DIVA test, with infected animals
having anti-PPRV N and anti-PPRV H antibodies, while
the vaccinees will only have anti-PPRV H antibodies.
There are existing, well established and validated com-
mercially available cELISAs for both anti-N and anti-H
antibodies, making this an attractive DIVA test.
Despite their successful use in several trials as vectors
for human vaccines, the FP-based vaccines elicited very
poor antibody responses in goats, as well as poor cell-
mediated immune responses. The low level of responses
in small ruminants may be due to apoptosis of FP virus-
infected antigen presenting cells in these animals, as has
been shown recently in cattle [37]. Because of the low
level of immune response to the PPRV proteins
expressed from the FP vectors, we did not pursue these
constructs through to challenge, since they would not be
useful DIVA vaccines even if effective in protecting the
vaccinated animals from PPRV.
Replication-deficient adenovirus-vectored vaccines in-
duce potent CD8+ and CD4+ T-cell responses as well as
high antibody responses [53], and appear to be safe [54].
Furthermore, the Ad vector also acts as an adjuvant
[55]. Adjuvant effects in experimental vaccines have
been demonstrated by co-expressing cytokines such as
IL-2, IL-12 and GMCSF [56], presenting other options
for vaccine formulation. One of the drawbacks of Ad5-
vectored vaccines in humans has been that most people
have previously been infected with this virus, and the
pre-existing antibodies can inhibit the efficacy of the
vaccine [57]. However, vaccines based on Ad5 may be
suitable for use in livestock since these animals will not
have pre-existing immunity to the vector. Large scale
production of Ad viruses can be achieved [58] and,furthermore, Ad viruses can be made more thermostable
and efficacious in a range of formulations that further
promote stability [59,60].
Vaccination of goats with Ad-H, alone or with a simi-
lar dose of Ad-F, induced levels of H-specific, neutralis-
ing antibodies within 2 to 3 weeks that were comparable
to those induced by live, attenuated PPRV vaccines
[40,61]. Furthermore, these antibodies were maintained
for several months following vaccination. While this
work was in progress, similar Ad constructs were re-
ported [62], which induced a similar level of neutralising
antibody as that described in the present study, follow-
ing a single dose of replication defective Ad-H. In an-
other recent study, replication competent canine
adenovirus expressing PPRV H was also found to be ef-
fective at eliciting neutralising antibody in goats [63].
Unfortunately, neither of these studies went on to deter-
mine the ability of the Ad-vectored vaccines to protect
against virulent PPRV. This is important, as the critical
elements of the immune response required for protec-
tion against PPRV are not yet known. While the current
live attenuated PPRV vaccine induces neutralising anti-
body, and a titre > 1:10 is used as a marker for compe-
tency of preparations of such vaccines, attenuated
morbillivirus vaccines also induce cell-mediated immun-
ity [64,65], which may also be important in protection.
We have demonstrated that vaccination with Ad-H, or
Ad-H and Ad-F, induced a potent effector memory CD8+
response in goats, although the number of H-specific
CD8+ IFNγ+ cells had declined to basal levels by 15 weeks
post-vaccination. Further studies are therefore needed to
determine the effect of Ad-H vaccination on persistence
of central memory CD8+ T cells in goats. No detailed
studies have been carried out to establish the mecha-
nisms of protection induced by live, attenuated PPRV
vaccines. However, studies on rinderpest showed that in-
duction of neutralising antibodies by vaccination with
purified viral proteins did not protect against infection
[66], suggesting that it is not possible to deduce protec-
tion based on antibody alone. We therefore analysed the
ability of Ad-vectored vaccines to protect against infec-
tion with virulent PPRV, and demonstrated that a single
dose of Ad expressing the PPRV H protein can protect
against PPRV challenge up to 4 months after vaccin-
ation. Furthermore, vaccinated goats did not appear to
excrete infectious virus from the nasopharynx, suggest-
ing that they may not transmit virus to susceptible,
unvaccinated animals. This is the first time that an
Ad-vectored vaccine has been shown to protect against
virulent PPRV challenge, and shows that the immune
responses elicited by the replication-defective vaccine
are sufficient to protect the vaccinated animal from in-
fection, with a protective response that is sustained for
at least 4 months. Longer term studies will be required
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antibodies induced by Ad-H.
In the study by Wang et al. [62], it was suggested that
co-expression of F and H proteins induced higher levels
of neutralising antibody than vaccination with Ad ex-
pressing either F or H alone. This is a similar finding to
that seen in cattle vaccinated with vaccinia virus express-
ing RPV H, F or both H and F, where it was suggested
that the combination of H and F induced stronger pro-
tection against RPV [67]. In our studies, expression of H
alone (experiment 3) induced neutralising antibody titres
at least as high as those seen in animals vaccinated with
Ad-F plus Ad-H (experiment 2). This may be because
we gave a higher dose of Ad than that used by Wang
et al. [62], and the strength of the response to H alone,
coupled with the adjuvant effect of Ad, dominated any
co-operative effect of vaccination with Ad H and F
together.
This is the first time that the effect of virulent PPRV
infection on specific immune cell sub-sets has been ana-
lyzed. We have shown that whereas the proportion of
circulating WC1+ γ/δ T-cells and CD14+ monocyte/
macrophage cells did not change after PPRV infection of
control goats, there was a decrease in the proportion of
circulating CD4+ cells 4 days after challenge. This de-
crease may have been due, at least in part, to infection
with PPRV, as the proportion of CD4+ cells staining for
intracellular H was greater than that of CD8+ cells,
4 days after PPRV challenge. The reduction in CD4+
cells was not observed in any of the Ad-H vaccinated
animals. There was a slight increase in the percentage of
CD8+ T-cells at 7 days pc in all animals, suggesting in-
duction of CTL responses by PPRV infection. Co-
administration of Ad-GMCSF at the time of vaccination
appeared to have an effect on infection of CD4+ and
CD8+ cells with PPRV. These animals had lower levels
of detectable intracellular viral H protein in both the live
CD4+ and live CD8+ T cells 4 days after challenge, com-
pared with the other vaccine groups.
The contribution of GMCSF and IL-2 in boosting im-
mune responses to Ad vaccination is not clear from this
study. However, the results from the 2nd experiment sug-
gested that the combination of Ad-IL-2 and Ad-GMCSF
induced higher H-specific serum antibodies and a
greater H-specific CD8+ IFNγ+ response compared with
Ad-F and Ad-H alone. The level of N-specific antibodies
after challenge with PPRV was significantly lower in the
two vaccine groups that received Ad-IL-2 compared
with the other groups of goats, suggesting that there was
less replication of the challenge virus in these animals
and, therefore, that co-administration of Ad-IL-2 in-
duced a more effective protective immune response,
even though a significant effect on T cell responses, H-
specific or neutralising antibody levels was not seen. Itwill be interesting to determine if an adjuvant effect of
the co-expressed cytokines is more obvious at lower
doses of Ad-H/Ad-F. If such studies demonstrate that a
co-administered Ad-vectored cytokine has a dose spar-
ing effect on an Ad-vectored PPRV vaccine, then it may
be possible to construct a recombinant Ad, which can
have an insert of ~7.5 kb, expressing both PPRV H and
cytokine.
In conclusion, we have demonstrated that a single vac-
cination with a recombinant Ad expressing the PPRV H
protein induced PPRV-specific neutralising antibodies,
primed CD8+ T cells, was safe, and completely protected
goats against PPR for at least 4 months.
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